$ASRT has received three mentions from two distinct FinTwit voices over the past 12 months, with discussion focused on its acquisition by Garda Therapeutics. The ticker was first mentioned on 2026-03-27 by @microcapclub in a general discussion of active stocks, and has since been tracked primarily by @ssi_invest, which accounted for two mentions. The acquisition details include an $18.00 per share cash component plus a non-tradeable contingent value right tied to Sprix®, with a 20-day go-shop period that began in early April 2026 and a tender offer requiring simple majority approval. The most recent mention on 2026-04-27 noted that Garda was set to commence the tender offer on April 29, 2026, following expiration of the window-shop period, with closing expected in Q2 2026.